Cargando…

Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI

PURPOSE: The study aimed to construct a predictive model for clinically significant prostate cancer (csPCa) and investigate its clinical efficacy to reduce unnecessary prostate biopsies. METHODS: A total of 847 patients from institute 1 were included in cohort 1 for model development. Cohort 2 inclu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Zengni, Wang, Xinchao, Zhang, Wanchun, Gao, Kaisheng, Wang, Le, Qian, Lixia, Mu, Jingjun, Zheng, Zhongyi, Cao, Xiaoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990202/ https://www.ncbi.nlm.nih.gov/pubmed/36882854 http://dx.doi.org/10.1186/s12957-023-02959-1

Ejemplares similares

Performance of prostate health index and PSA density in a diverse biopsy‐naïve cohort with mpMRI for detecting significant prostate cancer
por: Carbunaru, Samuel, et al.
Publicado: (2021)

Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
por: Campistol, Miriam, et al.
Publicado: (2022)

Role of mpMRI of the prostate in screening for prostate cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2017)

Detection of clinically significant prostate cancer with PI-RADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions
por: Westphalen, Antonio C., et al.
Publicado: (2019)

AI-predicted mpMRI image features for the prediction of clinically significant prostate cancer
por: Li, Song, et al.
Publicado: (2023)

The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer
por: Zhang, Xin, et al.
Publicado: (2022)

Mischievous malakoplakia: A potential pitfall of mpMRI of the prostate?
por: Rezaee, Michael E., et al.
Publicado: (2020)

Pearls and pitfalls in diagnosing prostate cancer using multiparametric MRI (mpMRI)
por: Joshi, JJ, et al.
Publicado: (2015)

Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information
por: Han, Chao, et al.
Publicado: (2021)

Applications of Artificial Intelligence to Prostate Multiparametric MRI (mpMRI): Current and Emerging Trends
por: Bardis, Michelle D., et al.
Publicado: (2020)

bpMRI and mpMRI for detecting prostate cancer: A retrospective cohort study
por: Pan, Yongsheng, et al.
Publicado: (2023)

Optimising preoperative risk stratification tools for prostate cancer using mpMRI
por: Reisæter, Lars A. R., et al.
Publicado: (2017)

A multicenter study of artificial intelligence-aided software for detecting visible clinically significant prostate cancer on mpMRI
por: Sun, Zhaonan, et al.
Publicado: (2023)

The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study
por: Getaneh, Abraham M., et al.
Publicado: (2021)

Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy
por: Zhang, Fan, et al.
Publicado: (2022)

The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy
por: Nyk, Łukasz, et al.
Publicado: (2021)

Dynamic Contrast-Enhanced Study in the mpMRI of the Prostate—Unnecessary or Underutilised? A Narrative Review
por: Guljaš, Silva, et al.
Publicado: (2023)

Evaluation of the PI-RADS Scoring System for Classifying mpMRI Findings in Men with Suspicion of Prostate Cancer
por: Junker, Daniel, et al.
Publicado: (2013)

Transrectal Ultrasound in Prostate Cancer: Current Utilization, Integration with mpMRI, HIFU and Other Emerging Applications
por: Panzone, John, et al.
Publicado: (2022)

External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy
por: Pallauf, Maximilian, et al.
Publicado: (2022)

Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI
por: Her, E. J., et al.
Publicado: (2020)

Negative mpMRI Rules Out Extra-Prostatic Extension in Prostate Cancer before Robot-Assisted Radical Prostatectomy
por: Dinneen, Eoin, et al.
Publicado: (2022)

Quantib Prostate Compared to an Expert Radiologist for the Diagnosis of Prostate Cancer on mpMRI: A Single-Center Preliminary Study
por: Faiella, Eliodoro, et al.
Publicado: (2022)

Targeted 11C–choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy
por: Lazzeri, Massimo, et al.
Publicado: (2017)

Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy
por: Wei, G., et al.
Publicado: (2021)

Non-timely clinically applicable ADC ratio in prostate mpMRI: a comparison with fusion biopsy results
por: Falaschi, Zeno, et al.
Publicado: (2022)

Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer
por: Børretzen, Astrid, et al.
Publicado: (2023)

Exploring the efficacy of multi-flavored feature extraction with radiomics and deep features for prostate cancer grading on mpMRI
por: Khanfari, Hasan, et al.
Publicado: (2023)

An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines
por: Panebianco, Valeria, et al.
Publicado: (2017)

Effect of domain knowledge encoding in CNN model architecture—a prostate cancer study using mpMRI images
por: Sobecki, Piotr, et al.
Publicado: (2021)

Prostate minimally invasive procedures: complications and normal vs. abnormal findings on multiparametric magnetic resonance imaging (mpMRI)
por: Bui, Thanh-Lan, et al.
Publicado: (2021)

Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20 ng/ml before the initial biopsy
por: Li, Yu, et al.
Publicado: (2020)

Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [(68)Ga]PSMA-11-PET and [(11)C]Acetate-PET
por: Sandgren, Kristina, et al.
Publicado: (2023)

False-positive mpMRI and true-negative (68)Ga-PSMA PET/CT xanthogranulomatous prostatitis: a case report
por: Tang, Yongxiang, et al.
Publicado: (2022)

Radiomic Machine Learning and External Validation Based on 3.0 T mpMRI for Prediction of Intraductal Carcinoma of Prostate With Different Proportion
por: Yang, Ling, et al.
Publicado: (2022)

Focal Irreversible Electroporation for Localized Prostate Cancer – Oncological and Safety Outcomes Using mpMRI and Transperineal Biopsy Follow-Up
por: Gielchinsky, Ilan, et al.
Publicado: (2023)

Transrectal ultrasound examination of prostate cancer guided by fusion imaging of multiparametric MRI and TRUS: avoiding unnecessary mpMRI-guided targeted biopsy
por: Xu, Guang, et al.
Publicado: (2022)

Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET/CT imaging features in primary prostate cancer
por: Kesch, Claudia, et al.
Publicado: (2018)

Concordance between Preoperative mpMRI and Pathological Stage and Its Influence on Nerve-Sparing Surgery in Patients with High-Risk Prostate Cancer
por: Humke, Clara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pvuohe9ljnlulc40lto1js3sbb